Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty-six patients with bronchial carcinoid tumors were operated on over a 37-year period. The results were reviewed with special reference to presenting complaint, histological diagnosis, location of the tumor, lymphatic involvement, and type of surgical resection. Age at operation ranged from 9 to 86 years (mean, 43.6 years). Presenting symptoms were hemoptysis in 21 instances, chronic cough in 17, and pneumonia in 15. The primary tumor was within the main bronchus in 17 patients. Twenty-one patients required pneumonectomy, and 20 had lobectomy or bilobectomy . Nine of the patients under-going pneumonectomy had severely damaged lung tissue distal to the lesion in the main bronchus. Six patients had metastases to hilar nodes. Four patients died of carcinoid tumor, but none with metastases died of carcinoid tumor. This series confirms the low malignancy potential of bronchial carcinoid tumors, even in the presence of lymphatic involvement. Although conservative resection is an attractive surgical option, only 10 of the 46 (22%) were potential candidates for such intervention. Standard surgical resection resulted in "cure" in 90% of the patients in the series.
 ...
PMID:Bronchial carcinoid tumors. 673 49

Forty-nine patients with very advanced locoregional lung cancer, metastatic in 41% of the instances, were treated with 5 Gy once weekly to a total dose of 50 to 60 Gy (1826-2050 ret). The overall tumor response rate was 68% (27% complete response and 41% partial response). The largest number of responders and the majority of complete responses were seen with the higher doses (60 Gy). The response rates of the major histologic variants were 100%, 75%, and 47% for small cell, large cell, squamous, and adenocarcinomas. The time to achieve more than 50% reduction in tumor size was 2, 2, 6, and 9 weeks for these histologic variants, respectively. The overall incidence of local failures was 22%, with only 10% of the patients demonstrating exclusive in-field local failures. There are 13 long-term survivors and the main cause of patient deaths was metastatic disease. The technique was extremely well tolerated, and, in fact, practically no acute radiation-induced complications were observed during the 10 to 12 weeks' treatment duration. Only one patient developed a symptomatic but transient radiation pneumonitis. Radiation fibrosis of various degrees has occurred, but it has been mostly asymptomatic and analogous to what is normally seen using conventional continuous schedules delivering similar doses. Once-a-week irradiation emerges as a practical and convenient alternative for the treatment of lung cancer, and appears to achieve similar results to conventional continuous schedules.
 ...
PMID:Once-a-week radiation therapy for locally advanced lung cancer. Final report. 674 5

The purpose of this study was to detect possible factors related to the occurrence of DIC in carcinoma patients. I) We studied 20 carcinoma cases accompanied with DIC. Results; The carcinomas most frequently accompanied with DIC were cancers of the biliary system, gastric, hepatic and pancreatic cancer, especially those with distant metastases. Pneumonia, UTI and biliary tract infections seemed to be the most important triggers of DIC. No significant relationship was found between anti-cancer chemotherapy and the DIC incidence. Endotoxemia was more frequently detected in patients having received anti-cancer drugs than in those who not. II) The effects of anti-cancer chemotherapy on the incidence of endotoxemia was examined in rats. A higher incidence of endotoxemia was noted in the groups treated with high doses of 5-FU or Cyclophosphamide. The incidence of endotoxemia seemed to run parallel with the incidence of diarrhea and of weight loss in each animal group.
 ...
PMID:[Clinical and experimental studies on DIC found in carcinoma; correlation between anti-cancer drug administration and endotoxemia]. 687 46

A survey of sheep with chronic respiratory tract disease was conducted in the central sierra of Peru. Histopathologic examinations coupled with an agar-gel immunodiffusion test for ovine progressive pneumonia (OPP) revealed that sheep pulmonary adenomatosis and OPP were present in these flocks. Of 80 sheep examined, 22 had lesions of sheep pulmonary adenomatosis, and 4 had metastases to regional lymph nodes. Four sheep had lesions consistent with OPP and 9 had lesions indicating the coexistence of both diseases. The agar-gel immunodiffusion test revealed that at least 26% of the sheep had been exposed to the OPP (or an antigenically similar) virus. A variety of other respiratory tract diseases complicated the evaluations of these sheep, including verminous pneumonia, hydatid disease, lung abscesses, and other nonspecific acute and chronic pneumonias.
 ...
PMID:Coexistence of pulmonary adenomatosis and progressive pneumonia in sheep in the central sierra of Peru. 688 71

As compared to control animals, guinea-pigs to the shaved backs of which a dose of 0.16 ml of a 0.12% solution of PES/100g. of body mass had been applied twice daily for periods of 28 and 90 d, respectively (5 d of application being followed by 2 d without treatment), showed erythema, loss of hair, slower increase in mass, increased heart rate, smaller body mass/kidney mass and body mass/spleen mass ratios, increases in leucocytes, ASAT, ALAT, LDH I and LDH III. In the 28-d test, slight inflammatory symptoms of the liver, kidneys and heart were observed in the experimental animals. These symptoms were more marked in the 90-d test, granulomata in the livers being particularly striking. A pneumonia of moderate to very marked degree is suggestive of the activation of a clinically latent PES infect whereby the inflammatory alterations in the kidneys might be explained by the formation of metastases.
 ...
PMID:[Subacute and subchronic percutaneous tolerance testing (28-day and 90-day test) of epicutaneously applied dis-infectants as demonstrated by the example of peroxyethanoic acid (author's transl)]. 707 Nov 11

Twelve children with malignant sacrococcygeal teratoma containing embryonal carcinoma, were treated at the Children's Hospital of Philadelphia between 1971 and 1980. Their ages at diagnosis ranged from 2 days to 23 mo; 8 of the 12 (67%) were girls. Five of the 12 patients presented with localized tumors which were grossly completely excised. Four received no further therapy, and all 4 recurred with histologically documented embryonal carcinoma. Despite subsequent treatment with radiation therapy (RT) and chemotherapy (vincristine, actinomycin D, and cyclophosphamide, collectively called VAC, in all 4 plus adriamycin in 3, only 1 has survived free of disease, 8 yr from diagnosis. The other 3 died of tumor (2) or pneumonia after pulmonary RT (1). The fifth patient in this group received VAC with adriamycin (total dose, 350 mg/sq m) and died of autopsy-proven cardiotoxicity without tumor. The remaining 7 patients presented with either unresectable local tumor (3) or distant metastases (4). One of these 7 died 6 days after biopsy with massive liver metastases. The other 6 children were treated after operation with VAC (5) or vincristine and actinomycin D (1) chemotherapy, and 5 also received RT to the pelvis. One has survived free of disease at 6 yr after treatment with VAC and adriamycin and pelvic RT, but the other 5 died of tumor (2) or of pneumonia after pulmonary RT (3). Surgery alone is inadequate for successful management of children with malignant sacrococcygeal teratoma. Chemotherapy with VAC, with or without adriamycin, can be effective when combined with radiation, but fatal pulmonary toxicity can result from such combined therapy. The optimal therapeutic program for children with malignant sacrococcygeal teratoma is still evolving.
 ...
PMID:Treatment strategies for infants with malignant sacrococcygeal teratoma. 727 58

We reviewed 69 patients with documented carcinoid tumors, 67 of whom had resectable disease. Operations included nine pneumonectomies, 31 lobectomies, 12 bilobectomies, five segmental resections, and 10 sleeve resections. Follow-up on 65 patients reveals 40 surviving beyond 5 years and 13 beyond 20 years since resection. There were no operative deaths and only one recurrence (local) that was subsequently successfully resected. Twenty patients had had recurrent unifocal pneumonitis or hemoptysis for up to 5 years prior to diagnosis. Two patients had the carcinoid syndrome. Biopsy was performed on 23 tumors and resulted in "moderate-to-severe" hemorrhage in six cases. Lymphatic spread was present in seven cases. All seven are alive and free of disease, six of whom have been followed from 5 to 24 years. Diseased resection margins were present in two cases, with both surviving 20 years after resection. All 10 sleeve resections were performed more than 5 years ago. We conclude that carcinoid tumors carry a favorable prognosis upon resection, even when intrathoracic lymphatic metastases are present and are resected. Lung-sparing resections including sleeve resections should be utilized. Recurrent pneumonia or hemoptysis or both requires diligent investigation. Biopsy of the tumors may be performed with care.
 ...
PMID:Bronchial carcinoid tumors: twenty years' experience. 735 32

Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma. Objective evidence of tumor regression was seen in 4 patients. Given prior to preoperative radiation therapy, COPP produced partial remissions in 2 patients, making possible smaller radiation treatment fields. Two patients with pleural involvement when first seen, achieved tumor regression when COPP was given prior to radical radiation therapy. One of these patients remains disease-free at 34 months; the other succumbed to pneumonitis. One patient, presenting with pleural metastasis three years after undergoing incomplete resection of thymoma, failed to respond to treatment. Combination chemotherapy with COPP can produce objective regression of invasive lymphoepithelial thymomas which may be useful in the preoperative management of selected cases, as well as in the management of unresectable or metastatic disease.
 ...
PMID:Combination chemotherapy in invasive thymoma role of COPP. 741 54

42 patients with metastases to the lung and 7 patients with metastases to the liver received a combined treatment with polychemotherapy and local gamma-irradiation simultaneously. Radiation doses to the lung were mostly 15 Gy in 12 days up to 18 Gy in 2 1/2 weeks (657 to 731 ret). Right and left lung were never treated at the same time. Thus, treatment results could be compared and severe side effects were avoided. Regression of metastases occurred more often after a combined treatment, and remission lasted longer. Pneumonitis was seen in 1/3 of all cases but could be managed satisfactorily by antiphlogistics. Metastases to the liver, too, responded well to a combined treatment.
 ...
PMID:[Combination of chemotherapy and local radiation therapy for metastases to the lung or liver: indication and results (author's transl)]. 742 64

There is a high probability for patients with locally advanced, unresectable, nonmetastatic, nonsmall-cell bronchogenic carcinoma (NSCBC) to harbor subclinical distant metastases at diagnosis. Approximately 30% will disseminate in the first three months and an additional 50% will disseminate before a year has elapsed. Twenty advanced nonmetastatic patients with NSCBC were treated with localized split-course chest irradiation (LCI) plus total body body (upper and lower half-body) irradiation for occult metastases. Thirty equally advanced, nonmetastatic patients, who were treated with only localized split-course chest irradiation, were matched and served as a retrospective control group. The first 11 patients received HBI after LCI (Pilot Study No. 1), but five (45%) had evidence of distant metastases before UHBI was delivered. This was not different from the control group where 11 (37%) of the patients had evidence of distant dissemination less than 2 1/2 months from the onset of treatment. The remaining nine patients received UHBI first followed by LCI and LHBI (Pilot Study No. 2); only one (11%) had evidence of distant metastases in the first 2 1/2 months. Apparently, the median recurrence free survival, metastatic free interval, and median survival were significantly prolonged, and there was a decrease in the incidence of liver metastases in patients receiving HBI for occult metastases over the patients of the control group. An increase in local tumor control was seen when large single doses of UHBI were added to LCI. Although elective HBI seems to delay the appearance of distant metastases, it did not prevent their occurrence, alter patterns of first relapse, or significantly improve the overall survival. Nevertheless, a therapeutic gain may have been achieved and is discussed. These two high-risk Phase II Pilot Studies for the Eastern Cooperative Oncology Group (ECOG) have served as the basis for a larger randomized protocol where this therapeutic strategy will be tested against other therapies. The incidence of radiation pneumonitis with 800 rad of UHBI corrected for lung transmission was 9%, or one of 11 patients. A hypothesis and rationale for a more effective combined modality therapy in these patients is given.
 ...
PMID:Total (half-body) systemic irradiation for occult metastases in non-small cell lung cancer: an Eastern Cooperative Oncology Group pilot report. 742 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>